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THE USE OF SURVIVAL ANALYSES FOR COST-EFFECTIVENESS 
MODELS: AN EVALUATION OF METHODS USED IN NICE APPRAISALS
Guyot P1, Ouwens M2
1Mapi Values Netherlands BV, Houten, The Netherlands, 2Mapi Values Netherlands B.V., 
Houten, The Netherlands
BACKGROUND AND OBJECTIVE: In the area of oncology and cardiovascular 
disease, treatments often effect overall survival, progression free survival and other 
time-to-event outcomes. For such treatments, the evaluation of cost-effectiveness 
often implies an extrapolation of trial results to periods beyond the trial length. The 
choice of extrapolation function may have a substantial impact on the mean survival: 
in some of our projects, the mean survival using the log-normal and log-logistic 
distribution was more than 1.5 times larger than the mean survival using the weibull 
distribution. This triggered us to perform an evaluation of methods used for extrapola-
tion in NICE submissions, in order to know which methods were accepted. METHODS: 
CEAs published between 2004 and 2008 by the NICE Technology Appraisal pro-
gramme, which included failure-time outcome(s), were systematically reviewed 
with respect to curve ﬁtting procedures used for extrapolation. RESULTS: In the 
HTA reports, exponential, weibull, log-logistic or log-normal curves were ﬁtted. 
The distribution was chosen based on face-value, by comparing it with the Kaplan 
Meier Curve. The quality of the graphical methods is limited, especially because the 
three curves often have a comparable ﬁt. In the reports, the proportional hazard 
assumption was used to compare the treatment arm with the comparator arm, often 
without assessing the validity of the assumption. CONCLUSION: The choice of 
methods used to extrapolate survival curves in HTA reports has been inadequately 
justiﬁed, and has under-estimated uncertainty. In our opinion, researchers should: 
assess the validity of proportional hazards and use different methodology when the 
assumption is violated; evaluate goodness-of-ﬁt more appropriately. Consider using 
a generalized distribution, for which the weibull, log-logistic and log-normal are 
special cases.
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OBJECTIVES: To describe a novel approach to modelling the outcomes, costs 
and cost-effectiveness of disease-modifying drugs (DMDs) that delay disability pro-
gression in multiple sclerosis (MS). METHODS: MS natural history was modelled 
using Kaplan-Meier survival distribution estimates for 18 expanded disability status 
scale (EDSS) endpoints (1.0 to 9.5) in each of 40 years since MS onset (YSO). NH 
estimates were based on 1,607 individuals with 6,993 clinic visits to the Dalhousie 
MS Research Unit (DMSRU), Nova Scotia, Canada, over 25 years (1979–2004). DMD 
effectiveness was measured as the relative increase in YSO between EDSS endpoints 
and was derived from DMSRU data and the literature. DMDs were modelled as a 
class and were not differentiated by speciﬁc drug. To measure health outcomes as 
quality adjusted life years (QALYs), EDSS disability scores were converted to HUI3 
scores. DMD treatment gains were estimated by the difference in QALYs experienced 
by the NH and DMD cohorts over 40 YSO. Annual DMD costs, net of foregone 
EDSS-speciﬁc health care costs, were derived from person-level DMSRU data linked 
to Nova Scotia health services utilization data. Cost-effectiveness of DMDs was mea-
sured as cost/QALY gained. Costs and QALYs were discounted by 3% annually. 
Key scenario parameters include DMD treatment eligibility, YSO at DMD start, 
DMD switching and stopping, initial and ﬁnal MS classiﬁcation, analysis horizon and 
discount rate. RESULTS: The results reﬂect the increased time to EDSS endpoints 
with DMD therapy and demonstrate the feasibility of using person-level data and 
a Kaplan-Meier approach to model costs and outcomes in MS with and without 
DMDs. CONCLUSIONS: This novel approach incorporates much more detailed 
MS natural history, DMD effectiveness and cost data than earlier models, allowing a 
more precise representation of the clinical and economic impact of MS DMD treat-
ment programs.
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EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-
ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C
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OBJECTIVES: A standard approach to economic evaluation is to conduct a meta-
analysis to subsequently inform a decision-analytical model. An innovative approach 
is to implement the meta-analysis and model evaluation simultaneously, in a Bayesian 
framework. These approaches were compared in two Markov models for chronic 
hepatitis C (CHC), where transition probabilities were not directly observable. 
METHODS: We updated a published meta-analysis on progression rates in CHC. 
Included studies provided distributions of patients by disease severity level, for differ-
ent durations of infection. Two structures were considered to model disease progres-
sion: one with three states (“mild CHC”, “moderate CHC”, cirrhosis), another more 
complex with ﬁve states. The following methodological approaches were compared: 
1) the “standard” approach involving successively maximum-likelihood estimation of 
progression rates for each study, random-effect meta-analysis of resulting estimates, 
Markov model evaluation and probabilistic sensitivity analysis, and 2) an integrated 
approach with estimation of progression rates and model evaluation in one Monte 
Carlo Markov Chain simulation procedure. The impact of methodological approach 
and model structure on predicted numbers of cirrhotic patients and total costs 
from NHS perspective at 20 years was analysed. RESULTS: The ﬁve-state model pre-
dicted the following proportions of cirrhotic patients: 39.6% (standard deviation: 
0.075) and 50.2% (0.019) with approaches (1) and (2). The 3-state structure provided 
lower estimates: 19.7% (0.0911) and 22.3% (0.011) with approaches (1) and (2). For 
the 5-state model, predicted costs per patient were £7,120 (934) and £8,000 (856) 
with each approach respectively. CONCLUSIONS: The comprehensive modelling 
approach lead to higher mean estimates with lower variability than the standard 
approach. The simpler three-state structure seems to underestimate the burden of 
disease. The latter ﬁnding may have relevance for modelling progressive diseases more 
generally.
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MARGINAL STRUCTURAL MODELS FOR COMPARING THE 
EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL 
STUDIES
Desai R, Johnson M
University of Houston, Houston, TX, USA
OBJECTIVES: Longitudinal studies comparing treatments in real-world practice set-
tings may be threatened by bias due to time-dependent confounding from factors 
predicted by the treatment history. While standard statistical methods may fail to 
control this type of confounding, Marginal Structural Models (MSM) can be a better 
alternative. The objective of this paper is to illustrate the ﬁtting of a MSM to compare 
more than two treatments. METHODS: MSMs apply inverse probabilities of treatment 
weights (IPTW), which can be derived from multinomial logistic regression models 
for predicting probability of treatments and censoring in a particular time period. 
IPTW are then used in a Generalizing Estimating Equation (GEE) to estimate the 
causal effect of treatment on outcome. In this study, data from a national cohort of 
patients diagnosed with Chronic Heart Failure (CHF) from October 1, 1996(FY 1997) 
to September 30, 2002 (FY 2002) in the VA were used (n  19,569). The treatment 
groups were deﬁned based on the time-varying utilization of different angiotensin 
receptor blockers (ARB): candesartan, irbesartan, losartan, telmisartan, valsartan or 
no ARB each month starting from their ﬁrst prescription ﬁll in FY 2001 and FY 2002. 
The outcome assessed was mortality during the same time period. In addition to 
adjusting for sociodemographic factors, comorbidities, comedications hospitalization 
was the time-varying confounder considered. RESULTS: Hospitalization changed the 
predicted probabilities of treatment over time. In adjusted models, compared to 
Losartan, all the ARBs had similar effectiveness in reducing mortality except for 
telmisartan, which was associated with increased risk (OR 1.77, 95% CI  1.01–3.09). 
The no ARB group had the highest risk of mortality (OR 2.76, 95% CI  2.33–3.27). 
CONCLUSIONS: Marginal structural models can be used efﬁciently to compare more 
than two treatments in longitudinal observational studies where time dependent 
confounding affected by previous treatment may pose a serious threat to internal 
validity.
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A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH 
RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE 
ACROSS 36 MONTH
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OBJECTIVES: To analyze the change in health-related quality-of-life (HrQoL) in a 
cohort of patients with Parkinson’s disease(PD) and to identify different groups of 
HrQol patterns across 36 months. METHODS: Clinical parameters(Uniﬁed PD rating 
scale (UPDRS), Beck depression inventory(BDI)) and HrQoL data(EuroQol) were 
assessed in a cohort of 145 PD assessed at baseline, 3, 6, 12, 18, and 36 months. 31 
patients were lost to follow-up. EQ-5D data were analyzed with a piecewise growth 
mixture model(gender, UPDRS and BDI adjusted model parameters) to identify dis-
tinct HrQoL trajectory groups. RESULTS: The average overall EQ-5D was .58 at 
baseline(BL) followed by a moderate decline(dec) of .12 across 36 months. However, 
we found a remarkable heterogeneity between patient’s trajectories. A Latent Growth 
Model was applied resulting in a four-class model of distinct patterns in the EQ-5D 
course. Class one included patients with a moderate level of clinical parameter 
severity(UPDRS, BDI) at baseline and an almost constant high EQ-5D index score(BL: 
.80, dec: .07) during 36 months. Class two reﬂected the average HrQoL course of the 
whole PD population with a minimal decline during 36 months(EQ5D BL .56; dec 
.01). The third group consisted mainly(88%) of patients who passed away during the 
observation time and therefore had a large HrQoL decline(EQ-5D BL: .60; dec .4). 
Class four was characterized by a low level of EQ-5D at baseline(.36) and a signiﬁcant 
subsequent decline(.16). CONCLUSIONS: Present ﬁndings provide a more elaborate 
understanding of the variability of HrQoL reduction in PD over time. The classiﬁca-
tion of different HrQol subgroups may help to understand PD patients’ responsiveness 
to the natural history of disease. Future research is needed to enable the identiﬁcation 
of certain responder subgroups in terms of HrQoL upon different treatment regimens. 
This may also allow a more targeted and systematic PD therapy.
